Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab monotherapy in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
2017-000562-30Phase 3Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Incidence of high-grade treatment-related select adverse events. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-000562-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000562-30.